(Q39351008)

11 September 2017

Immunotherapy for malignant mesothelioma: Reality check (English)

1 reference

11 September 2017

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27669108%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Bibhusal Thapa

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27669108%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

D Neil Watkins

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27669108%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

26 September 2016

1 reference

Expert Review of Anticancer Therapy

11 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27669108%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27669108%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27669108%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

1167-1176

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27669108%20AND%20SRC:MED&resulttype=core&format=json

Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Global magnitude of reported and unreported mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Asbestos exposure during home renovation in New South Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Dual roles of immune cells and their factors in cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Immune evasion in cancer: Mechanistic basis and therapeutic strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Immunity, Inflammation, and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Role of transforming growth factor Beta in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Tumor necrosis factor receptor 1-mediated signaling is required for skin cancer development induced by NF-kappaB inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Costimulatory and coinhibitory receptors in anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Targeting immune checkpoints: New opportunity for mesothelioma treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Immunotherapy in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

CTLA-4 suppresses proximal TCR signaling in resting human CD4(+) T cells by inhibiting ZAP-70 Tyr(319) phosphorylation: a potential role for tyrosine phosphatases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

CTLA-4-Ig regulates tryptophan catabolism in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Tumor Immunotherapy Directed at PD-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

PD-1 and PD-1 ligands: from discovery to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Immunotherapy for malignant pleural mesothelioma. Current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II–III malignant pleural mesothelioma☆

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1241149

10.1080/14737140.2016.1241149

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27669108%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference